Does Aetna (CVS Health) Cover Rezdiffra (Resmetirom)? Prior Authorization, Formulary Tier, and Appeal Steps
Resmetirom, sold under the brand name Rezdiffra, is an oral thyroid hormone receptor-beta (THR-beta) selective agonist. It received FDA accelerated approval in March 2024 as the first medication indicated specifically for adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) who have moderate-to-advanced liver fibrosis, staged F2 or F3. It is prescription-only and not FDA-approved for weight loss or for earlier-stage fatty liver disease without significant fibrosis.
Aetna, including CVS Health-branded commercial plans, generally treats Rezdiffra as a covered specialty pharmacy drug rather than an excluded one. That is the useful starting point, but it is not the useful ending point. The real question for most readers is not whether Rezdiffra appears on an Aetna formulary somewhere, but whether a specific plan's prior authorization (PA) criteria, step-therapy rules, and specialty-pharmacy routing will actually clear on the first submission, because Aetna does not publish one universal policy that applies identically to every commercial, Medicare Advantage, and self-funded employer plan it administers.
Aetna commercial plans typically cover Rezdiffra (resmetirom) for its FDA-labeled population, adults with MASH and stage F2-F3 fibrosis, but coverage is gated by prior authorization and, on many plans, documented step therapy; the drug is almost always placed on a specialty formulary tier with dispensing routed through CVS Specialty. Exact PA criteria, tier number, and cost-sharing percentages vary by the specific Aetna plan (commercial, Medicare Advantage, or self-funded employer) and by plan year, so the only way to get a binding answer for an individual patient is to check that plan's current formulary and PA policy bulletin directly rather than relying on a general summary.
No Aetna-published policy bulletin for Rezdiffra was available in the source material for this article. Everything below describing Aetna's specific criteria, tier placement, and cost-sharing is a generalization based on how large commercial payers typically structure coverage for accelerated-approval specialty drugs with a narrow FDA label, not a verified quote from an Aetna document. Treat the specifics as a starting hypothesis to confirm, not a guarantee.
What is established versus what needs verification
- Established: Rezdiffra has FDA accelerated approval for MASH with F2-F3 fibrosis in adults, dated March 2024. This is confirmed by the FDA application record.
- Established, generally true across large commercial payers: New, high-cost specialty drugs with a narrow, biomarker-defined label are placed on a specialty tier and require prior authorization. This is a standard industry pattern, not something specific to Aetna that can be cited to a document here.
- Plausible but not verified in this draft: The specific PA checklist items (fibrosis staging method, step-therapy list, lab recency window), the exact formulary tier number, and the coinsurance percentage described in earlier drafts of this page. These read as reasonable and consistent with how MASH drug coverage tends to be structured, but no Aetna-specific source was available to confirm them, and they should be verified against the member's actual plan documents before anyone relies on them for a treatment or appeal decision.
- Not established: Any claim that a specific dollar copay, out-of-pocket maximum, or step-therapy exception will apply to an individual reader's plan. Self-funded employer plans administered by Aetna can set their own specialty drug rules, and Medicare Advantage or Medicaid managed-care plans run under separate formularies from commercial PPO/HMO products.
How to find your plan's actual answer
Because this page cannot see your specific Aetna plan document, the fastest reliable path is:
- Log in to your Aetna member portal or call the number on your insurance card and ask for the Rezdiffra (resmetirom) prior authorization policy bulletin by name.
- Ask your prescriber's office to request the same PA criteria through their provider portal or CoverMyMeds, since prescribers often get a more detailed clinical checklist than the member-facing summary.
- Confirm separately whether your plan is commercial, Medicare Advantage, or a self-funded employer plan administered by Aetna, since the rules can differ meaningfully between these.
What Aetna's coverage decision is likely built around
Large payers generally align specialty-drug PA criteria with the FDA label and the pivotal trial that supported approval. For Rezdiffra, that trial is commonly referred to as MAESTRO-NASH, a phase 3 randomized trial in adults with biopsy-confirmed MASH and fibrosis. Published reports describe a meaningfully higher rate of MASH resolution without worsening fibrosis, and a higher rate of fibrosis improvement, in resmetirom-treated patients compared with placebo at 52 weeks. The exact percentages and confidence intervals should be verified against the primary trial publication before being used in a letter of medical necessity; this draft intentionally does not restate specific numeric results here because the citation trail for those numbers could not be confirmed as accurate for this article.
Documentation that tends to matter in a PA submission for a drug like this, based on how MASH staging and thyroid-related drug monitoring generally work clinically, includes:
- Confirmed MASH diagnosis with fibrosis staging (liver biopsy is the reference standard; noninvasive tools such as transient elastography, ELF score, or FIB-4 are sometimes accepted, but acceptance criteria are payer-specific and should be confirmed)
- Prescriber specialization in hepatology, gastroenterology, or documented liver-disease expertise
- Recent relevant labs, since resmetirom's mechanism involves thyroid hormone receptor activity in the liver and baseline thyroid function (TSH, free T4) is a recognized monitoring consideration for this drug class
- Documentation of prior lifestyle intervention and, on plans that require step therapy, a documented trial of or contraindication to other MASH-directed measures
If a step-therapy requirement applies and the patient has a contraindication to a step agent, or has rapidly progressing fibrosis, documenting that clearly and specifically is generally what supports a step-therapy exception request, though the exact exception pathway is plan-specific and should be confirmed with Aetna rather than assumed.
Cost and formulary tier: what can and cannot be said with confidence
Resmetirom is expensive relative to most oral chronic-disease medications, consistent with its specialty classification and accelerated-approval status. A precise, dated list price and a precise coinsurance percentage were part of the source draft but could not be verified against a current, citable source for this rewrite, so they are not restated here as fixed figures. What can be said reliably:
- Specialty-tier drugs on Aetna plans are typically dispensed through CVS Specialty, and many Aetna plans restrict specialty dispensing to that pharmacy rather than allowing an outside specialty pharmacy.
- Out-of-pocket cost for a specialty-tier drug depends on whether the plan uses coinsurance (a percentage of cost) or a flat copay, and on where the patient is in their deductible and out-of-pocket maximum for the plan year. These figures change annually and by plan, so a number quoted for one plan year or one plan design should not be assumed to apply to another.
- Manufacturer copay assistance programs for branded specialty drugs commonly exist and can lower out-of-pocket cost for commercially insured patients, but federal anti-kickback rules generally bar their use for patients on Medicare, Medicaid, or other government-funded insurance. Whether a specific program exists for Rezdiffra, and its current terms, should be confirmed directly with the manufacturer's patient support resources rather than assumed from this page.
Appealing a denial
If Aetna denies a Rezdiffra prior authorization, the general structure of a commercial insurance appeal in the United States is a first-level internal appeal followed, if unsuccessful, by an independent external review conducted by a party not affiliated with the insurer. Internal appeal filing windows and external review windows vary by state and by plan type, so the specific number of days to file should be taken from the denial letter itself and from the state insurance department, not assumed from a generic description.
A useful letter of medical necessity generally restates, in one place, why the documentation already submitted meets the FDA label population (MASH with F2-F3 fibrosis), why the prescriber's specialty and the fibrosis staging method satisfy the plan's stated criteria, and why any step-therapy step was completed or is contraindicated. Citing the pivotal trial by name and describing its design (a phase 3 randomized trial comparing resmetirom to placebo in biopsy-confirmed MASH with fibrosis) is reasonable; citing specific percentage results should wait until the prescriber's office has confirmed the current, correct figures from the primary publication or the FDA-approved labeling.
Two claims from earlier versions of pages like this one deserve a specific flag: a quoted statement attributed to a named MAESTRO-NASH investigator, and a quoted statement attributed to a named hepatologist at a professional conference, cannot be verified from the source material available for this rewrite and have been removed rather than repeated. If either quotation is genuine and properly sourced, it should be reinstated with a direct citation to the recorded talk or publication, not carried forward as an unattributed quote.
Decision framework: what changes what you should do next
| Your situation | What it changes | Suggested next step |
|---|---|---|
| You have a confirmed MASH diagnosis but fibrosis stage is based on ultrasound only, not biopsy or elastography | Most PA criteria for this drug class hinge on documented F2-F3 staging; ultrasound alone is usually insufficient | Ask your prescriber whether a FibroScan, ELF test, or biopsy is feasible and reasonable before submitting a PA, since this is the most common reason for denial |
| Your plan is a self-funded employer plan administered by Aetna | Specialty drug coverage rules can be set by the employer and may differ from Aetna's standard commercial policy | Ask HR or the plan administrator for the plan's own specialty drug and step-therapy language, not just Aetna's general policy |
| You are on an Aetna Medicare Advantage or Medicaid managed-care plan | Part D and Medicaid formularies and PA criteria are frequently different from commercial plans and may lag commercial coverage decisions | Call the Medicare Advantage or Medicaid plan's member services line directly and ask specifically about Rezdiffra, since a commercial-plan answer does not transfer |
| You have a documented contraindication to standard step-therapy agents (for example, a contraindication to pioglitazone or vitamin E) | This is generally the strongest basis for a step-therapy exception, stronger than simply not having tried the agent | Have the prescriber document the specific contraindication by name on the PA form rather than describing it generally |
| Your fibrosis is progressing on serial imaging over months, not stable | Clinical urgency can support both a step-therapy exception and an expedited appeal if a denial occurs | Ask the prescriber to include dated serial elastography or biopsy results showing the trajectory, and to consider certifying an expedited appeal if a denial happens |
| Your PA was denied for a reason not listed above | The denial letter's stated reason is the only thing that matters for the appeal, not a generic explanation | Read the denial letter's specific reason code and have the prescriber's letter of medical necessity respond to that reason point by point |
When to seek urgent care rather than wait on a coverage decision
Prior authorization and appeal timelines, even expedited ones, are not designed to resolve within hours. If a patient develops signs of acute liver decompensation (new jaundice, confusion, significant abdominal swelling, or gastrointestinal bleeding) while waiting on a coverage decision for resmetirom or any MASH treatment, that is an emergency department situation, not a pharmacy benefits question, and should not wait on an insurance appeal.
Questions this page can and cannot answer
Is Rezdiffra covered for weight loss under Aetna? No. It is not FDA-approved for weight loss, and coverage is built around the MASH-with-fibrosis indication.
Can my primary care doctor prescribe it and have Aetna cover it? Many specialty drug policies for MASH restrict prescribing to hepatology, gastroenterology, or documented liver-disease expertise; a PCP may need a specialist consultation note. Confirm the exact prescriber requirement with Aetna, since generalist prescribing rules vary by plan.
How long does a PA decision take? Timelines vary by submission method and plan; electronic PA platforms are generally faster than fax submissions, and federal and most state rules require expedited decisions within a short window when a prescriber certifies urgency. Exact business-day timelines should be confirmed with Aetna for the specific plan.
What if I cannot get an answer on tier or cost before treatment decisions need to be made? Ask the prescriber's office to initiate a benefits investigation through CVS Specialty before finalizing a treatment plan; specialty pharmacies routinely run these investigations as part of onboarding a new specialty prescription.
This version removes several specific figures, a specific out-of-pocket maximum dollar amount, specific coinsurance percentages, an AMA denial-rate statistic, and two attributed quotations that appeared in an earlier draft, because none of these could be verified against a confirmed, correctly matched primary source at the time of this rewrite. It replaces them with a description of what is generally true about specialty-drug coverage patterns and a clear instruction to verify plan-specific numbers directly with Aetna. This page has not undergone medical review; it is prepared for editorial and qualified medical review before publication.
References
- U.S. Food and Drug Administration. Rezdiffra (resmetirom) NDA overview, application number 217785. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217785
Other citations referenced in earlier drafts of this page (specific PubMed identifiers for the MAESTRO-NASH trial, the PIVENS vitamin E/pioglitazone trial, AASLD practice guidance, an AMA prior authorization survey, and Endocrine Society or AACE guidance) could not be confirmed as correctly matched to their stated claims during this rewrite and have been described narratively rather than linked. An editor with primary literature access should locate and re-attach the correct identifiers before publication.